title: Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP.
abstract: The loss of dopaminergic neurons in Parkinson's disease is associated with a glial reaction and the overproduction of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha). TNF-alpha acts via two different receptors, TNFR1 and TNFR2, and is believed to have both a neuroprotective and a deleterious role for neurons. In order to analyze the putative role of TNF-alpha in parkinsonism, we compared the effect of the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice lacking TNFR1, TNFR2, or both receptors and in wild-type littermates. We show that MPTP does not affect spontaneous activity or anxiety in any of the groups and that it reduces motor activity on a rotarod in double knock out mice but not in mice lacking only one receptor. Postmortem analysis revealed no differences in the number of nigral dopaminergic neurons whatever the group. In contrast, striatal dopamine level was slightly decreased in double knock-out mice and more reduced by MPTP in this group than in the other groups of mice. In addition, dopamine turnover was significantly more increased in double knock out mice after MPTP injection. These data suggest that TNF-alpha does not participate in the death of dopaminergic neurons in parkinsonism but that it slightly alters dopamine metabolism or the survival of dopaminergic terminals by a mechanism involving both receptors.
authors.affiliation: Hôpital Lariboisière AP-HP, 75010, Paris, France.
authors.forename: Estelle
authors.initials: E
authors.lastname: Rousselet
authors.forename: Jacques
authors.initials: J
authors.lastname: Callebert
authors.forename: Karine
authors.initials: K
authors.lastname: Parain
authors.forename: Chantal
authors.initials: C
authors.lastname: Joubert
authors.forename: Stéphane
authors.initials: S
authors.lastname: Hunot
authors.forename: Andreas
authors.initials: A
authors.lastname: Hartmann
authors.forename: Claude
authors.initials: C
authors.lastname: Jacque
authors.forename: Fernando
authors.initials: F
authors.lastname: Perez-Diaz
authors.forename: Charles
authors.initials: C
authors.lastname: Cohen-Salmon
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Launay
authors.forename: Etienne C
authors.initials: EC
authors.lastname: Hirsch
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage* / Q000494:pharmacology*; D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D004298:Dopamine / Q000235:genetics / Q000378:metabolism; D020267:MPTP Poisoning / Q000235:genetics / Q000378:metabolism* / Q000503:physiopathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009043:Motor Activity / Q000187:drug effects / Q000235:genetics; D018124:Receptors, Tumor Necrosis Factor / Q000172:deficiency* / Q000235:genetics; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D015703:Antigens, CD; D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D047889:Receptors, Tumor Necrosis Factor, Type II; D014409:Tumor Necrosis Factor-alpha; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine